TheRyte (UK)

TheRyte is a Liverpool-based bioscience company founded in 2001 which has developed a compound with proven biological activity against a broad-spectrum anticancer target. This development is based on a completely new and breakthrough understanding of how cancer works discovered by Professor Hilmar Warenius, a clinical oncologist at the University of Liverpool, and is highly cancer cell specific without any observed adverse effects on normal cells. For more information, visit

Vantia (US/UK)

Vantia is an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets. Formed in 2008 as a spin-out of Ferring Research Ltd’s small molecule R&D, it has two clinical phase products, VA106483 for the treatment of nocturia and VA111913 for the treatment of dysmenorrhoea, as well as preclinical and discovery programmes based on protease inhibition with potential in the areas of oncology and inflammation. The company’s investors include MVM Life Science Partners, SV Life Sciences and Novo A/S. Vantia is situated on Southampton Science Park, UK. For more information, see